nodes	percent_of_prediction	percent_of_DWPC	metapath
Alprenolol—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.135	0.137	CbGbCtD
Alprenolol—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.127	0.129	CbGbCtD
Alprenolol—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.127	0.129	CbGbCtD
Alprenolol—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.115	0.116	CbGbCtD
Alprenolol—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.115	0.116	CbGbCtD
Alprenolol—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.0991	0.1	CbGbCtD
Alprenolol—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.0962	0.0974	CbGbCtD
Alprenolol—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.087	0.0881	CbGbCtD
Alprenolol—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.087	0.0881	CbGbCtD
Alprenolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000358	0.0287	CbGpPWpGaD
Alprenolol—ADRB2—GPCRs, Other—ACKR1—acquired immunodeficiency syndrome	0.000339	0.0272	CbGpPWpGaD
Alprenolol—ADRB3—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000273	0.0219	CbGpPWpGaD
Alprenolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000217	0.0174	CbGpPWpGaD
Alprenolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000213	0.0171	CbGpPWpGaD
Alprenolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000208	0.0167	CbGpPWpGaD
Alprenolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000204	0.0163	CbGpPWpGaD
Alprenolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000196	0.0157	CbGpPWpGaD
Alprenolol—ADRB3—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000165	0.0133	CbGpPWpGaD
Alprenolol—ADRB1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000162	0.013	CbGpPWpGaD
Alprenolol—ADRB2—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000158	0.0127	CbGpPWpGaD
Alprenolol—HTR1A—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000155	0.0124	CbGpPWpGaD
Alprenolol—ADRB3—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.00015	0.012	CbGpPWpGaD
Alprenolol—ADRB3—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000142	0.0114	CbGpPWpGaD
Alprenolol—ADRB3—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00014	0.0112	CbGpPWpGaD
Alprenolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000134	0.0108	CbGpPWpGaD
Alprenolol—ADRB3—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000133	0.0107	CbGpPWpGaD
Alprenolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000129	0.0103	CbGpPWpGaD
Alprenolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000126	0.0101	CbGpPWpGaD
Alprenolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000123	0.00988	CbGpPWpGaD
Alprenolol—ADRB2—GPCRs, Other—CCR5—acquired immunodeficiency syndrome	0.000122	0.00978	CbGpPWpGaD
Alprenolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000121	0.00972	CbGpPWpGaD
Alprenolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000117	0.00934	CbGpPWpGaD
Alprenolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000114	0.00914	CbGpPWpGaD
Alprenolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000114	0.00914	CbGpPWpGaD
Alprenolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000114	0.00914	CbGpPWpGaD
Alprenolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000112	0.00894	CbGpPWpGaD
Alprenolol—ADRB3—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000102	0.00819	CbGpPWpGaD
Alprenolol—ADRB1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	9.82e-05	0.00787	CbGpPWpGaD
Alprenolol—ADRB2—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	9.6e-05	0.0077	CbGpPWpGaD
Alprenolol—HTR1A—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	9.39e-05	0.00753	CbGpPWpGaD
Alprenolol—ADRB3—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	9.24e-05	0.00741	CbGpPWpGaD
Alprenolol—ADRB3—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	9.13e-05	0.00731	CbGpPWpGaD
Alprenolol—ADRB1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	8.88e-05	0.00711	CbGpPWpGaD
Alprenolol—ADRB3—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	8.69e-05	0.00696	CbGpPWpGaD
Alprenolol—ADRB3—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	8.69e-05	0.00696	CbGpPWpGaD
Alprenolol—ADRB2—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	8.68e-05	0.00696	CbGpPWpGaD
Alprenolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	8.68e-05	0.00696	CbGpPWpGaD
Alprenolol—HTR1A—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	8.66e-05	0.00694	CbGpPWpGaD
Alprenolol—HTR1A—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	8.57e-05	0.00687	CbGpPWpGaD
Alprenolol—HTR1A—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	8.49e-05	0.00681	CbGpPWpGaD
Alprenolol—ADRB3—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	8.49e-05	0.0068	CbGpPWpGaD
Alprenolol—ADRB1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	8.41e-05	0.00674	CbGpPWpGaD
Alprenolol—ADRB1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	8.31e-05	0.00666	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	8.28e-05	0.00663	CbGpPWpGaD
Alprenolol—ADRB2—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	8.22e-05	0.00659	CbGpPWpGaD
Alprenolol—HTR1A—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	8.15e-05	0.00653	CbGpPWpGaD
Alprenolol—HTR1A—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	8.15e-05	0.00653	CbGpPWpGaD
Alprenolol—ADRB2—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	8.13e-05	0.00652	CbGpPWpGaD
Alprenolol—HTR1A—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	8.04e-05	0.00644	CbGpPWpGaD
Alprenolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	7.96e-05	0.00638	CbGpPWpGaD
Alprenolol—HTR1A—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	7.95e-05	0.00637	CbGpPWpGaD
Alprenolol—ADRB1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	7.9e-05	0.00633	CbGpPWpGaD
Alprenolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	7.82e-05	0.00627	CbGpPWpGaD
Alprenolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	7.79e-05	0.00624	CbGpPWpGaD
Alprenolol—ADRB2—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	7.73e-05	0.0062	CbGpPWpGaD
Alprenolol—ADRB3—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	7.68e-05	0.00615	CbGpPWpGaD
Alprenolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	7.62e-05	0.0061	CbGpPWpGaD
Alprenolol—HTR1A—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	7.56e-05	0.00606	CbGpPWpGaD
Alprenolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	7.2e-05	0.00577	CbGpPWpGaD
Alprenolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	7.05e-05	0.00565	CbGpPWpGaD
Alprenolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	6.89e-05	0.00552	CbGpPWpGaD
Alprenolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	6.77e-05	0.00543	CbGpPWpGaD
Alprenolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	6.77e-05	0.00543	CbGpPWpGaD
Alprenolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	6.62e-05	0.00531	CbGpPWpGaD
Alprenolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	6.62e-05	0.00531	CbGpPWpGaD
Alprenolol—ADRB3—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	6.61e-05	0.0053	CbGpPWpGaD
Alprenolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	6.48e-05	0.00519	CbGpPWpGaD
Alprenolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	6.48e-05	0.00519	CbGpPWpGaD
Alprenolol—HTR1A—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	6.2e-05	0.00497	CbGpPWpGaD
Alprenolol—ADRB1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	6.06e-05	0.00486	CbGpPWpGaD
Alprenolol—ADRB3—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	5.95e-05	0.00477	CbGpPWpGaD
Alprenolol—ADRB2—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	5.93e-05	0.00475	CbGpPWpGaD
Alprenolol—HTR1A—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	5.8e-05	0.00465	CbGpPWpGaD
Alprenolol—HTR1A—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	5.58e-05	0.00447	CbGpPWpGaD
Alprenolol—ADRB1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	5.48e-05	0.0044	CbGpPWpGaD
Alprenolol—ADRB1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	5.42e-05	0.00434	CbGpPWpGaD
Alprenolol—ADRB2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	5.37e-05	0.0043	CbGpPWpGaD
Alprenolol—ADRB2—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	5.3e-05	0.00425	CbGpPWpGaD
Alprenolol—HTR1A—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	5.25e-05	0.0042	CbGpPWpGaD
Alprenolol—ADRB3—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	5.24e-05	0.0042	CbGpPWpGaD
Alprenolol—ADRB3—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	5.22e-05	0.00419	CbGpPWpGaD
Alprenolol—HTR1A—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	5.18e-05	0.00415	CbGpPWpGaD
Alprenolol—ADRB1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	5.16e-05	0.00413	CbGpPWpGaD
Alprenolol—ADRB1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	5.16e-05	0.00413	CbGpPWpGaD
Alprenolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	5.15e-05	0.00413	CbGpPWpGaD
Alprenolol—ADRB2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	5.04e-05	0.00404	CbGpPWpGaD
Alprenolol—ADRB2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	5.04e-05	0.00404	CbGpPWpGaD
Alprenolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	5.04e-05	0.00404	CbGpPWpGaD
Alprenolol—ADRB1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	5.04e-05	0.00404	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.01e-05	0.00402	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.01e-05	0.00402	CbGpPWpGaD
Alprenolol—HTR1A—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	4.93e-05	0.00395	CbGpPWpGaD
Alprenolol—HTR1A—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	4.93e-05	0.00395	CbGpPWpGaD
Alprenolol—ADRB2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	4.93e-05	0.00395	CbGpPWpGaD
Alprenolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	4.93e-05	0.00395	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	4.91e-05	0.00394	CbGpPWpGaD
Alprenolol—ADRB3—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4.91e-05	0.00393	CbGpPWpGaD
Alprenolol—ADRB3—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4.91e-05	0.00393	CbGpPWpGaD
Alprenolol—HTR1A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	4.82e-05	0.00386	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	4.8e-05	0.00385	CbGpPWpGaD
Alprenolol—ADRB3—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.74e-05	0.0038	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	4.7e-05	0.00377	CbGpPWpGaD
Alprenolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	4.64e-05	0.00372	CbGpPWpGaD
Alprenolol—ADRB1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	4.56e-05	0.00365	CbGpPWpGaD
Alprenolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	4.54e-05	0.00364	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.53e-05	0.00363	CbGpPWpGaD
Alprenolol—ADRB3—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.46e-05	0.00357	CbGpPWpGaD
Alprenolol—ADRB3—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.46e-05	0.00357	CbGpPWpGaD
Alprenolol—ADRB2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	4.46e-05	0.00357	CbGpPWpGaD
Alprenolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	4.44e-05	0.00356	CbGpPWpGaD
Alprenolol—HTR1A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	4.36e-05	0.00349	CbGpPWpGaD
Alprenolol—ADRB1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	3.92e-05	0.00314	CbGpPWpGaD
Alprenolol—ADRB2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	3.84e-05	0.00308	CbGpPWpGaD
Alprenolol—HTR1A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	3.75e-05	0.00301	CbGpPWpGaD
Alprenolol—ADRB3—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.74e-05	0.00299	CbGpPWpGaD
Alprenolol—ADRB3—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.68e-05	0.00295	CbGpPWpGaD
Alprenolol—ADRB1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	3.53e-05	0.00283	CbGpPWpGaD
Alprenolol—ADRB2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	3.46e-05	0.00277	CbGpPWpGaD
Alprenolol—ADRB3—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.39e-05	0.00272	CbGpPWpGaD
Alprenolol—HTR1A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	3.38e-05	0.00271	CbGpPWpGaD
Alprenolol—ADRB3—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.37e-05	0.0027	CbGpPWpGaD
Alprenolol—ADRB3—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.34e-05	0.00268	CbGpPWpGaD
Alprenolol—HTR1A—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	3.26e-05	0.00261	CbGpPWpGaD
Alprenolol—ADRB1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	3.11e-05	0.00249	CbGpPWpGaD
Alprenolol—ADRB1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	3.1e-05	0.00248	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.1e-05	0.00248	CbGpPWpGaD
Alprenolol—ADRB3—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.06e-05	0.00245	CbGpPWpGaD
Alprenolol—ADRB2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	3.04e-05	0.00244	CbGpPWpGaD
Alprenolol—ADRB2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	3.03e-05	0.00243	CbGpPWpGaD
Alprenolol—HTR1A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	2.98e-05	0.00239	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.98e-05	0.00238	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.98e-05	0.00238	CbGpPWpGaD
Alprenolol—HTR1A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	2.96e-05	0.00238	CbGpPWpGaD
Alprenolol—ADRB1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	2.91e-05	0.00234	CbGpPWpGaD
Alprenolol—ADRB1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	2.91e-05	0.00234	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.91e-05	0.00233	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.91e-05	0.00233	CbGpPWpGaD
Alprenolol—ADRB2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	2.85e-05	0.00228	CbGpPWpGaD
Alprenolol—ADRB2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	2.85e-05	0.00228	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.85e-05	0.00228	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.85e-05	0.00228	CbGpPWpGaD
Alprenolol—ADRB1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.81e-05	0.00226	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.8e-05	0.00225	CbGpPWpGaD
Alprenolol—HTR1A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	2.79e-05	0.00223	CbGpPWpGaD
Alprenolol—HTR1A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	2.79e-05	0.00223	CbGpPWpGaD
Alprenolol—ADRB2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.75e-05	0.00221	CbGpPWpGaD
Alprenolol—HTR1A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.69e-05	0.00216	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.69e-05	0.00216	CbGpPWpGaD
Alprenolol—ADRB1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.65e-05	0.00212	CbGpPWpGaD
Alprenolol—ADRB1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.65e-05	0.00212	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.63e-05	0.00211	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.63e-05	0.00211	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.63e-05	0.00211	CbGpPWpGaD
Alprenolol—HTR1A—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	2.63e-05	0.00211	CbGpPWpGaD
Alprenolol—ADRB2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.59e-05	0.00207	CbGpPWpGaD
Alprenolol—ADRB2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.59e-05	0.00207	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.57e-05	0.00206	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	2.56e-05	0.00206	CbGpPWpGaD
Alprenolol—HTR1A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.53e-05	0.00203	CbGpPWpGaD
Alprenolol—HTR1A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.53e-05	0.00203	CbGpPWpGaD
Alprenolol—ADRB1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.22e-05	0.00178	CbGpPWpGaD
Alprenolol—ADRB1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.18e-05	0.00175	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	2.18e-05	0.00175	CbGpPWpGaD
Alprenolol—ADRB2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.17e-05	0.00174	CbGpPWpGaD
Alprenolol—ADRB2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.14e-05	0.00171	CbGpPWpGaD
Alprenolol—HTR1A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.12e-05	0.0017	CbGpPWpGaD
Alprenolol—HTR1A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.09e-05	0.00167	CbGpPWpGaD
Alprenolol—ADRB1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.01e-05	0.00161	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2e-05	0.00161	CbGpPWpGaD
Alprenolol—ADRB1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2e-05	0.0016	CbGpPWpGaD
Alprenolol—ADRB1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.98e-05	0.00159	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.97e-05	0.00158	CbGpPWpGaD
Alprenolol—ADRB2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.97e-05	0.00158	CbGpPWpGaD
Alprenolol—ADRB2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.95e-05	0.00157	CbGpPWpGaD
Alprenolol—ADRB3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.94e-05	0.00156	CbGpPWpGaD
Alprenolol—ADRB2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.94e-05	0.00155	CbGpPWpGaD
Alprenolol—HTR1A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.93e-05	0.00154	CbGpPWpGaD
Alprenolol—HTR1A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.91e-05	0.00153	CbGpPWpGaD
Alprenolol—HTR1A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.9e-05	0.00152	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.84e-05	0.00147	CbGpPWpGaD
Alprenolol—ADRB1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.81e-05	0.00145	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.81e-05	0.00145	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.8e-05	0.00144	CbGpPWpGaD
Alprenolol—ADRB2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.77e-05	0.00142	CbGpPWpGaD
Alprenolol—ADRB3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.77e-05	0.00141	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.76e-05	0.00141	CbGpPWpGaD
Alprenolol—HTR1A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.73e-05	0.00139	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.66e-05	0.00133	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.63e-05	0.0013	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.59e-05	0.00127	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.56e-05	0.00125	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.56e-05	0.00125	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.53e-05	0.00123	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.53e-05	0.00123	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.5e-05	0.0012	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.5e-05	0.0012	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.19e-05	0.000953	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.17e-05	0.000939	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.16e-05	0.000932	CbGpPWpGaD
Alprenolol—ADRB1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.15e-05	0.000925	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.15e-05	0.000918	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.14e-05	0.000912	CbGpPWpGaD
Alprenolol—ADRB2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.13e-05	0.000905	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.12e-05	0.000898	CbGpPWpGaD
Alprenolol—HTR1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.1e-05	0.000885	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.07e-05	0.000859	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.05e-05	0.00084	CbGpPWpGaD
Alprenolol—ADRB1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.05e-05	0.00084	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.04e-05	0.000836	CbGpPWpGaD
Alprenolol—ADRB3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.04e-05	0.000832	CbGpPWpGaD
Alprenolol—ADRB2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.03e-05	0.000822	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.02e-05	0.000821	CbGpPWpGaD
Alprenolol—HTR1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1e-05	0.000803	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.19e-06	0.000496	CbGpPWpGaD
Alprenolol—ADRB1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.16e-06	0.000494	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.13e-06	0.000491	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.06e-06	0.000485	CbGpPWpGaD
Alprenolol—ADRB2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.03e-06	0.000483	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.92e-06	0.000475	CbGpPWpGaD
Alprenolol—HTR1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.89e-06	0.000472	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	4.47e-06	0.000358	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.64e-06	0.000292	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.56e-06	0.000285	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.48e-06	0.000279	CbGpPWpGaD
